Brenipatide

Last updated

Brenipatide
Clinical data
Other namesLY-3537031; LY3537031
Routes of
administration 		Subcutaneous injection [1] [2]
Drug class GLP-1 receptor agonist; GIP receptor agonist
Identifiers
  • D-Tyrosyl-2-methylalanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-L-leucyl-L-α-aspartyl-L-lysyl-N6-[N-(19-carboxy-1-oxononadecyl) -L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-2-[2-(2-aminoethoxy)ethoxy]acetyl] -L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-α-glutamyl-α-methyl-L-tyrosyl-L-leucyl-L-isoleucyl-L-alanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
PubChem SID
UNII
Chemical and physical data
Formula C228H354N46O72
Molar mass 4891.590 g·mol−1

Brenipatide (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name LY-3537031) is a dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist which is under development for the treatment of alcoholism, bipolar disorder, asthma, smoking withdrawal, cardiovascular disorders, liver disorders, metabolic disorders, and obesity. [1] [2] It is taken by subcutaneous injection once per month. [1] [2] The drug has a longer elimination half-life than tirzepatide or retatrutide. [2] Brenipatide is under development by Eli Lilly and Company. [1] As of December 2025, it is in phase 3 clinical trials for alcoholism and bipolar disorder, phase 2 trials for asthma and smoking withdrawal, and phase 1 trials for cardiovascular disorders, liver disorders, metabolic disorders, and obesity. [1]

See also

References

  1. 1 2 3 4 5 "Brenipatide - Eli Lily and Company". AdisInsight. 22 December 2025. Retrieved 13 January 2026.
  2. 1 2 3 4 Østergaard S (December 2025). "Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides". Expert Opinion on Drug Discovery: 1–24. doi:10.1080/17460441.2025.2601113. PMID   41381216. Brenipatide is a once-monthly dual-acting peptide from Eli Lilly that targets GLP-1R and GIPR (Table 1) and is currently in a Phase 3 clinical trial for moderate-to-severe alcohol use disorder (NCT07219966). Although it has a single C20 diacid, it exhibits a longer half-life than tirzepatide and retatrutide, likely because of a backbone optimized for stability against enzymatic degradation through a Trp to αMe-Tyr substitution.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.